ØU Biotech nr.8/2017 - Inkl. analyse af Novo Nordisks Q1'17
ADDvise, Alligator Bioscience, AstraZeneca, Bactiguard, BioGaia, BioInvent, Biotec Pharmacon, Biovica, Brighter, Camurus, Diamyd Medical, ExpreS2ion, FIT Biotech, Genmab, Genovis, Immune Pharmaceuticals, Karessa, Lundbeck, Medivir, Navamedic, NeuroVive, Onxeo, PCI Biotech, Photocure, PledPharma, Saniona, Targovax og Wilson Therapeutics.